Cost-Utility Analysis of Ingenol Mebutate Versus Imiquimod 5% for Actinic Keratosis Treatment In Spain

  • Ortega-Joaquin N
  • Elías I
  • de la Cueva P
  • et al.
N/ACitations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Objectives: To estimate the incremental cost utility ratio (ICUR) for ingenol mebutate vs imiquimod 5% for actinic keratosis (AK) patient's treatment on the face and scalp, in Spain. Methods: A Markov model was used to simulate AK patient treatment evolution for a 5-year horizon from the Spanish National Health System (NHS). Duration of ingenol mebutate treatments was 3 days and 12 days for imiquimod 5%. Effectiveness measure was total clearance rate obtained from indirect mixed comparisons (42.24% for ingenol mebutate and 44.54% for imiquimod) and adjusted according compliance (90% for ingenol mebutate and 60% for imiquimod). Annual recurrence rate (20%) derived from literature. Annual discount rate of 3% was applied for costs and outcomes. Total cost estimation (€ ,2015) included: drug (retail price VAT included with mandatory deduction), and dermatology visits cost (for adverse events and disease management). Utilities values (0.986 for AK and 1 for clearance) were used to derive quality-adjusted-life years (QALY). Probabilistic and deterministic sensitivity analyses were performed to confirm the robustness of the obtained results. Results: Ingenol mebutate showed higher effectiveness than imiquimod 5%, 0.535 vs 0.503 total gained clearances and 4.451 vs 4.449 total QALYs and accounted higher total costs, € 551.50 (46% drug cost) versus € 527.89 (36% drug cost) compared to imiquimod 5%. Estimated ICUR was € 10.906/QALY gained with ingenol mebutate vs imiquimod 5%. In probabilistic sensitivity analysis performed, 78% of simulations yielded an ICUR below € 30,000/QALY for ingenol mebutate versus imiquimod. Conclusions: Ingenol mebutato vs imiquimod 5% was an efficient alternative for NHS for patients with AK, on face and scalp, considering an acceptable threshold of € 30,000/QALY.

Cite

CITATION STYLE

APA

Ortega-Joaquin, N., Elías, I., de la Cueva, P., Del Pozo, L., Boada, A., Moreno, D., … Oyagüez, I. (2015). Cost-Utility Analysis of Ingenol Mebutate Versus Imiquimod 5% for Actinic Keratosis Treatment In Spain. Value in Health, 18(7), A423. https://doi.org/10.1016/j.jval.2015.09.569

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free